Abstract: A peptide disinfectant for preventing coronaviruses is provided. The peptide disinfectant for preventing coronaviruses comprises an active ingredient of the peptide disinfectant comprises mixed peptides comprising a first peptide (SEQ ID NO. 01), a second peptide (SEQ ID NO. 02), and a third peptide (SEQ ID NO. 03).

Abstract: The present invention provides peptides that are synthetic modifications of Polar Assonant (PA) peptide including C-terminal PEGylation. The invention further provides methods of using least one synthetic peptide for regulating the complement system and interacting with neutrophils to alter their binding and activity.

Abstract: The present invention relates to a hemostatic elastin-like polypeptide comprising a glutamine embedded in a Q-block sequence and, optionally, a lysine embedded in a K-block sequence. Under physiological setting, the Q-block sequence and the K-block sequence are recognized by human transglutaminase factor XIIIa and crosslinked with fibrin networks. The present invention also relates to the medical use of the polypeptide, to a nucleic acid sequence encoding the polypeptide, to an expression vector comprising the nucleic acid sequence, and to a cell comprising the nucleic acid sequence or the expression vector.

Abstract: The present disclosure provides inhibitory peptides of mitochondrial fission protein 1 (Fis1), polynucleotides and vectors encoding the peptides, and methods of using the peptides to treat diseases, including arterial diseases and vascular dysfunction associated with type 2 diabetes.

Abstract: The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory bicyclic compounds, as well as to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.

Abstract: The invention generally concerns a novel class of cyclopentane modified FIT-PNA (cpFIT-PNA) probes and uses thereof.

Abstract: Methods and compositions for increasing the production of large amounts of empty capsids of the foot-and-mouth disease virus (FMDV) in a stable manner in mammalian cells by regulating the expression of FMDV 3C protease. The instant methods and compositions are based on the fact that a decreased expression of 3C protease results in a reduced cell toxicity and an increased synthesis of viral capsid proteins, as well as production of recombinant empty capsids. The invention provides recombinant plasmids that direct the expression of P1, 3C, and the use of the plasmids for producing new stable cell lines capable of generating high titers of FMDV empty capsids. The invention provides methods for regulating the expression of the FMDV 3C protease gene at a transcriptional and translational level in order to achieve the required process level of 3C protease for the selection process, as well as the production process.

Abstract: Polypeptides that comprise axle or ring components of protein nanomachines, and kits and nanomachines including such polypeptides are disclosed herein.

Abstract: The present disclosure provides variant OmpG polypeptides, compositions comprising the OmpG variant polypeptides, and methods for using the variant OmpG polypeptides as nanopores for determining the sequence of single stranded nucleic acids. The variant OmpG nanopores reduce the ionic current noise versus the parental OmpG polypeptide from which they are derived and thereby enable sequencing of polynucleotides with single nucleotide resolution. The reduced ionic current noise also provides for the use of these OmpG nanopore variants in other single molecule sensing applications, e.g., protein sequencing.

Abstract: The present invention provides chimeric klebicins by combining translocation, receptor-binding, and bactericidal domains originated from different klebicins to achieve improved target cell range and bactericidal activity. Also provided are related compositions, kits, and methods of use of these chimeric klebicins.

Abstract: The present invention provides a composition comprising a chimeric fusion protein and immunmodulators that are supported on a carrier together with a solution as a vehicle. In other aspects the invention is related to associated polynucleotides, chimeric peptides, and methods for the preparation of the composition and for the prevention of bacterial infections in fish by administration of an oral vaccine form.

Abstract: Compositions and methods for modifying the production levels of alkaloids in plants are provided. Alkaloid production can be genetically controlled by modulating the transcriptional activation of PMT genes mediated by members of the ERF family and/or Myc family of transcription factors. Novel nucleotide sequences encoding the Myc family of transcription factors are also provided.

Abstract: The present disclosure provides recombinant polypeptides, nucleic acids encoding the recombinant polypeptides and methods for using these polypeptides and/or nucleic acids in enhancing or inducing an immune response in a subject in need thereof. The present disclosure also provides methods of treating a cell proliferative disorder, such as cancer, by administering the disclosed polypeptides and/or nucleic acids to a subject in need thereof.

Abstract: An antibacterial polypeptide and methods of use are described.

Abstract: Provided are unique affibodies specific for bone morphogenetic protein 2 (BMP-2), vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), platelet-derived growth factor (PDGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), inteleukin-4 (IL-4), and glial derived neurotrophic factor (GDNF), and well as hydrogels that include the affibodies and the corresponding protein. Also provided are methods of using the hydrogels, for example to treat bone injury, wounds, and neuron injury. In some examples, the hydrogel includes at least two different affibodies specific for the same protein, but have different disassociation constants (KD).

Abstract: Provided herein are mutant interleukin-10 polypeptides, and fusion polypeptides comprising the mutant interleukin-10 polypeptides and antigen binding molecules. The present disclosure provides methods of modulating immune cell function by contacting the immune cell with fusion polypeptides of the present disclosure. In addition, the disclosure also provides polynucleotides encoding the disclosed fusion molecules, and vectors and host cells comprising such polynucleotides. The present disclosure further provides methods for producing the fusion molecules, pharmaceutical compositions comprising the same, and uses thereof.

Abstract: IL-12 variants are provided. Also provided are antibodies that specifically bind to PD1. Also provided are fusion proteins of IL-12 variants and anti-PD1 antibodies. Also provided are uses of these IL-12 variants, anti-PD1 antibodies, fusion proteins, and related compositions and methods.

Abstract: This disclosure relates, inter alia to: modified interleukin 2 (IL-2) polypeptides; RNA polynucleotides, DNA polynucleotides, non-viral vectors, and viral vectors encoding such modified IL-2 polypeptides; methods of making such modified IL-2 polypeptides and RNA polynucleotides, DNA polynucleotides, non-viral vectors, and viral vectors encoding same; and methods of using such modified IL-2 polypeptides and RNA polynucleotides, DNA polynucleotides, non-viral vectors, and viral vectors encoding same.

Abstract: The present invention relates to compositions and methods for preventing or treating canine pruritic disease, optionally wherein the canine pruritic disease is canine atopic dermatitis (AD) in general, and a synthetic canine interferon (IFN)-alpha (?) for use in said treatment or prophylaxis in particular, as well as a composition and method comprising the same and a method of production of the synthetic canine interferon-alpha.

Abstract: Compositions and methods for treating diabetes in a canine are provided. A viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding a canine insulin polypeptide.

Abstract: PD1-41BBL fusion proteins are provided. Accordingly, there is provided a PD1-41BBL fusion protein comprising a single amino acid linker between the PD1 and the 41BBL. Also there is provided a PD1-41BBL fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-41BBL fusion protein, host-cells expressing the PD1-41BBL fusion protein and methods of use thereof.

Abstract: Provided are methods of treating cancer (e.g., a urothelial cancer) that comprise administering a polypeptide (e.g. a fusion polypeptide) that comprises a SIRP?-D1 domain variant and an Fc domain variant in combination with an antibody-drug conjugate (e.g., enfortumab vedotin). Also provided are related kits.

Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGEEHSV (SEQ ID NO: 1) derived from the MAGE-B2 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.

Abstract: Disclosed herein are chimeric antigen receptors (“CARs”) comprising an antigen binding site that recognizes citrullinated polypeptides. Citrullinated polypeptides, such as citrullinated vimentin, fibrinogen, and filaggrin, are expressed in the synovium of subjects with rheumatoid arthritis. Further disclosed are T cells, and in particular, Treg cells, that express these CARs. Administration of these CAR-T cells is useful in the treatment of rheumatoid arthritis as well as other diseases associated with citrullinated peptides.

Abstract: The present invention provides polypeptides and nucleic acid molecules that are useful in identifying.

Abstract: Disclosed herein are extracellular vesicles comprising an immunomodulating component. Also provided are methods for producing the extracellular vesicles and methods for using the extracellular vesicles for treating cancer, GvHD, and autoimmune diseases.

Abstract: Chimeric molecules comprising a fibrinogen-related domain (FRED) from human fibrinogen-like protein 2 (FGL2) are provided. Immunomodulatory pharmaceutical compositions comprising the chimeric molecules, as well as methods for reducing inflammation and treating autoimmune disease in a subject by administering the chimeric molecules or immunomodulatory pharmaceutical compositions are also provided.

Abstract: The present invention relates to the field of therapeutic proteins, in particular, to recombinant coagulation factors. It provides a recombinant Factor VIII (FVIII) protein comprising specific point mutations at defined positions, which serve to reduce the immunogenicity of said FVIII protein, wherein the Factor VIII protein substantially retains its coagulant activity. It further provides nucleic acids encoding said de-immunized protein, cell lines and methods of recombinant preparation as well as pharmaceutical compositions comprising the recombinant FVIII of the invention, which are advantageous for use in treatment of patients with Hemophilia A, particularly those who have not yet been treated with a FVIII product. Additionally, it can be a safe alternative for previously treated patients and even for patients who have developed an immune-response to FVIII, e.g., for immune-tolerance-induction therapy (ITI/ITT) or rescue ITI.

Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.

Abstract: Methods for preparing mammalian cells for perfusion cell culture processes that improve the growth and productivity of the cells are provided. Also provided are cell culture methods that involve subjecting mammalian cells to one or more perfusion procedures, which involve generating a solids phase and a liquid phase with a continuous flow centrifuge, and utilizing at least a portion of the solids phase to sustain, maintain and/or initiate a new cell culture. Perfusion bioreactor systems and components thereof are also provided.

Abstract: A method for preparing a composition of human plasma-derived immunoglobulin M (IgM) includes PEG precipitation of the IgM, resuspension of the precipitated IgM; (c) performing an adsorption chromatography, removing isoagglutinins A/B, nanofiltration, and ultrafiltration/diafiltration. The precipitation can be performed at a pH between 4.5 and 6.5, and the PEG can be at a concentration between 5 (w/v) and 11% (w/v).

Abstract: Methods and compositions for treating a Staphylococcus aureus bloodstream infection in a human subject involve administering to the subject an antibody which specifically binds Staphylococcus aureus protein A (SpA) with a K D of less than 1×10?10 M via its Fab region paratope and is able to mediate opsonization of SpA-expressing Staphylococcus aureus bacteria in the presence of at least 1 mg/ml of IgG immunoglobulins which bind SpA via their Fc regions.

Abstract: Provided herein are antibodies and antibody compositions. Also provided are method for obtaining such antibodies and methods for using such antibodies and compositions for treating bacterial and viral infections and for research and screening purposes. The antibodies and compositions can affect the immune system and inhibiting pathogenic infections including streptococcal infections.

Abstract: The invention is directed to treatment or prevention of a disease characterized by deposition of A? in the brain using anti-N3pGlu A? antibodies. The diseases that can be treated or prevented include, e.g., Alzheimer's disease, Down's syndrome, and cerebral amyloid angiopathy. The invention, in some aspects, is related to doses and dosing regimens useful for such treatments. The invention is also related to, in some aspects, human subjects who are responsive to treatment or prevention of a disease characterized by deposition of A? in the brain using anti-N3pGlu A? antibodies. The invention is also related to human subject who have one or two alleles of APOE4.

Abstract: Provided herein are methods and cell-free systems for production of a recombinant antibody in which the antibody is directed against a target protein that is natively expressed as an intracellular protein. Also provided herein are modified cell-free systems for use in such methods in which the modified system is engineered to express a variant target protein that has a mutant epitope of the target epitope of an antibody.

Abstract: The present disclosure relates to antibodies and antibody conjugates having one or more site-specific mutations in the CH2 domain of the heavy chain. The antibody variants disclosed herein can have improved characteristics (e.g., thermal stability, antibody yields, antibody titers, cell-killing) relative to a parent or wild type antibody, including aglycosylated parent or wild type antibodies. Pharmaceutical compositions, diagnostic compositions and kits comprising the same, as well as methods of using these compositions and kits for therapeutic and diagnostic purposes, are also described.

Abstract: The disclosure relates generally to canine antibody variants and uses thereof. Specifically, the disclosure relates to mutations in the constant region of canine antibody for improving its half-life and other characters.

Abstract: The invention provides novel anti-NGF proteins, antibodies, and NGF-binding fragments thereof which inhibit association of NGF with TrkA and/or p75 and are suitable for administration to a canine or feline subject. The invention also provides novel compositions and methods of treating pain or eliciting an analgesic effect in a canine or feline subject, comprising administering an effective amount of an anti-NGF protein, antibody or fragment thereof. The methods and compositions are used to treat or prevent NGF-related disorders.

Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-? inhibitor, such as an anti-TNF-? antibody (e.g., golimumab).

Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.

Abstract: The invention is based on the surprising finding of antibodies that bind to an immunoglobulin-like (Ig) domain of the extra cellular domain (ECD) of IGSF11 (VSIG3) can also inhibit the interaction between IGSF11 and IGSF11 receptors such as VSIR (VISTA), the inhibition of such interaction can provide products, compositions and methods for treating diseases using antigen binding proteins targeting an Ig domain of IGSF11-ECD, including those being inhibitors of IGSF11-interaction with VSIR. Also provided are methods of sensitising cells involved with a proliferative disorder against the cytotoxic effect of cell-mediated immune responses, and/or to kill such cells and/or methods for treating proliferative diseases, using an IGSF11 inhibitor such as an antibody binding to an Ig domain of IGSF11-ECD, as well as certain related aspects including detection, diagnostic and screening methods.

Abstract: The present invention discloses an ROR1-targeted antibody or an antigen-binding fragment thereof, a preparation method therefor and use thereof, wherein the ROR1-targeted antibody or the antigen-binding fragment thereof comprises a VL and a VH; the VL comprises the following CDRs or mutations thereof: VL CDR1, VL CDR2 and VL CDR3 as set forth in SEQ ID NOs: 69, 78 and 84, respectively; the VH comprises the following CDRs or mutations thereof: VH CDR1, VH CDR2 and VH CDR3 as set forth in SEQ ID NOs: 12, 33 and 53, respectively. The antibody or the antigen-binding fragment thereof described above has good binding affinity to ROR1, has almost no cross-reactivity with ROR2, has a KD value comparable to that of the reference antibody in the prior art, has a significant endocytosis effect, and has an ADCC effect in tumor cells.

Abstract: Methods and compounds for conferring site-specific or local immune privilege, such as targeting to a cell expressing MAdCAM.

Abstract: Provided herein are novel antibody sequences that bind to CD147 and inhibit viral or parasite invasion, reduce inflammation, and reduce cancer cell viability. The present disclosure also provides methods of using these antibodies to treat viral infection and cancer.

Abstract: The present invention provides to a antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention relates to a nucleic acid sequence encoding the antibody construct, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention relates a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

Abstract: The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.

Abstract: The present invention relates to an LFA-1 signalling mediator with moderate LFA-1 stabilization properties for use in cancer immunotherapy or a composition for use in cancer immunotherapy comprising an immune system modulator, wherein the immune system modulator enhances the immune response against cancer, and an LFA-1 signalling mediator with moderate LFA-1 stabilization properties wherein the LFA-1 signalling mediator selectively and significantly enhances the anti-cancer immune response. The composition may comprise a carrier for target delivery of the composition.

Abstract: The present invention relates to methods for treating cancer comprising administering an antagonist of PD-1, e.g., anti-PD-1 antibody or antigen binding fragment thereof, and an anti-CTLA4 antibody or antigen binding fragment thereof, wherein the CTLA4 antibody or antigen binding fragment thereof is given at a fixed dose. Also provided are compositions and kits comprising a dosage of an anti-PD-1 antibody and a dosage of an anti-CTLA4 antibody, and uses thereof.

Abstract: An anti-CTLA4 (cytotoxic T lymphocyte associated antigen 4) and anti-PD-1 (programmed cell death 1) bifunctional antibody. a pharmaceutical composition thereof and use thereof. Particularly, the anti-CLTA4 and anti-PD-1 bifunctional antibody comprises a first protein functional domain that targets PD-1 and a second protein functional domain that targets CTLA-4. The bifunctional antibody can bind to CTLA-4 and PD-1 specifically, relieve immunosuppression of CTLA4 and PD-1 on an organism specifically, activate T lymphocytes, and thus has good application prospects.

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1), a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof and the use of the combination therapies for the treatment cancer.